tiprankstipranks
Context Therapeutics (CNTX)
NASDAQ:CNTX
US Market
CNTX
Context Therapeutics
RESEARCH TOOLSreports

Context Therapeutics (CNTX) Stock Forecast & Price Target

234 Followers
See the Price Targets and Ratings of:

CNTX Analyst Ratings

Strong Buy
7Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Context
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CNTX Stock 12 Month Forecast

Average Price Target

$5.43
▲(99.63% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Context Therapeutics in the last 3 months. The average price target is $5.43 with a high forecast of $7.00 and a low forecast of $3.02. The average price target represents a 99.63% change from the last price of $2.72.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","-1":"-$1","1.25":"$1.25","3.5":"$3.5","5.75":"$5.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.02,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.02</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.25,3.5,5.75,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.29,2.6523076923076925,3.014615384615385,3.376923076923077,3.7392307692307694,4.101538461538462,4.463846153846154,4.826153846153846,5.188461538461539,5.550769230769231,5.913076923076924,6.275384615384615,6.637692307692308,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.29,2.5315384615384615,2.773076923076923,3.0146153846153845,3.256153846153846,3.497692307692308,3.739230769230769,3.980769230769231,4.222307692307692,4.463846153846154,4.705384615384615,4.946923076923077,5.188461538461539,{"y":5.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.29,2.3461538461538463,2.4023076923076925,2.4584615384615383,2.5146153846153845,2.5707692307692307,2.626923076923077,2.683076923076923,2.7392307692307694,2.7953846153846156,2.8515384615384614,2.9076923076923076,2.963846153846154,{"y":3.02,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.05,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.887,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.551,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.862,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.588,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.71,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.849,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.969,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.37,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.29,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 68, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$7.00Average Price Target$5.43Lowest Price Target$3.02
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on CNTX
Charles Zhu
LifeSci Capital
LifeSci Capital
$6
Buy
120.59%
Upside
Reiterated
04/02/26
Analysts Are Bullish on These Healthcare Stocks: Femasys (FEMY), Context Therapeutics (CNTX)
Maxim Group Analyst forecast on CNTX
Jason McCarthy
Maxim Group
Maxim Group
$5
Buy
83.82%
Upside
Reiterated
04/02/26
Advancing Bispecific T‑Cell Engager Pipeline and Regulatory Milestones Underpin Buy Rating on Context
Piper Sandler Analyst forecast on CNTX
Biren Amin
Piper Sandler
Piper Sandler
$4→$7
Buy
157.35%
Upside
Assigned
03/24/26
Context Therapeutics price target raised to $7 from $4 at Piper SandlerContext Therapeutics price target raised to $7 from $4 at Piper Sandler
H.C. Wainwright Analyst forecast on CNTX
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
$5
Buy
83.82%
Upside
Reiterated
03/24/26
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (NASDAQ: PYXS), Nurix Therapeutics (NASDAQ: NRIX) and Context Therapeutics (NASDAQ: CNTX)
Guggenheim Analyst forecast on CNTX
Paul Jeng
Guggenheim
Guggenheim
$5
Buy
83.82%
Upside
Reiterated
03/23/26
Guggenheim Reaffirms Their Buy Rating on Context Therapeutics (CNTX)
William Blair Analyst forecast on CNTX
Matt Phipps
William Blair
William Blair
$3.02
Buy
11.03%
Upside
Reiterated
03/23/26
Analysts Are Bullish on These Healthcare Stocks: Sutro Biopharma (STRO), Context Therapeutics (CNTX)
JonesTrading Analyst forecast on CNTX
Soumit Roy
JonesTrading
JonesTrading
$7
Buy
157.35%
Upside
Assigned
01/23/26
JonesTrading Sticks to Its Buy Rating for Context Therapeutics (CNTX)
Cantor Fitzgerald Analyst forecast on CNTX
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
10/02/25
Context Therapeutics initiated with an Overweight at Cantor FitzgeraldContext Therapeutics initiated with an Overweight at Cantor Fitzgerald
Citizens JMP Analyst forecast on CNTX
Silvan Tuerkcan
Citizens JMP
Citizens JMP
$4
Buy
47.06%
Upside
Reiterated
06/03/25
Citizens JMP Remains a Buy on Context Therapeutics (CNTX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on CNTX
Charles Zhu
LifeSci Capital
LifeSci Capital
$6
Buy
120.59%
Upside
Reiterated
04/02/26
Analysts Are Bullish on These Healthcare Stocks: Femasys (FEMY), Context Therapeutics (CNTX)
Maxim Group Analyst forecast on CNTX
Jason McCarthy
Maxim Group
Maxim Group
$5
Buy
83.82%
Upside
Reiterated
04/02/26
Advancing Bispecific T‑Cell Engager Pipeline and Regulatory Milestones Underpin Buy Rating on Context
Piper Sandler Analyst forecast on CNTX
Biren Amin
Piper Sandler
Piper Sandler
$4→$7
Buy
157.35%
Upside
Assigned
03/24/26
Context Therapeutics price target raised to $7 from $4 at Piper SandlerContext Therapeutics price target raised to $7 from $4 at Piper Sandler
H.C. Wainwright Analyst forecast on CNTX
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
$5
Buy
83.82%
Upside
Reiterated
03/24/26
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (NASDAQ: PYXS), Nurix Therapeutics (NASDAQ: NRIX) and Context Therapeutics (NASDAQ: CNTX)
Guggenheim Analyst forecast on CNTX
Paul Jeng
Guggenheim
Guggenheim
$5
Buy
83.82%
Upside
Reiterated
03/23/26
Guggenheim Reaffirms Their Buy Rating on Context Therapeutics (CNTX)
William Blair Analyst forecast on CNTX
Matt Phipps
William Blair
William Blair
$3.02
Buy
11.03%
Upside
Reiterated
03/23/26
Analysts Are Bullish on These Healthcare Stocks: Sutro Biopharma (STRO), Context Therapeutics (CNTX)
JonesTrading Analyst forecast on CNTX
Soumit Roy
JonesTrading
JonesTrading
$7
Buy
157.35%
Upside
Assigned
01/23/26
JonesTrading Sticks to Its Buy Rating for Context Therapeutics (CNTX)
Cantor Fitzgerald Analyst forecast on CNTX
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
10/02/25
Context Therapeutics initiated with an Overweight at Cantor FitzgeraldContext Therapeutics initiated with an Overweight at Cantor Fitzgerald
Citizens JMP Analyst forecast on CNTX
Silvan Tuerkcan
Citizens JMP
Citizens JMP
$4
Buy
47.06%
Upside
Reiterated
06/03/25
Citizens JMP Remains a Buy on Context Therapeutics (CNTX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Context Therapeutics

3 Months
xxx
Success Rate
8/22 ratings generated profit
36%
Average Return
+3.55%
reiterated a xxx
 rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 36.36% of your transactions generating a profit, with an average return of +3.55% per trade.
1 Year
Jason McCarthyMaxim Group
Success Rate
4/10 ratings generated profit
40%
Average Return
+88.06%
reiterated a buy rating 5 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +88.06% per trade.
2 Years
xxx
Success Rate
10/10 ratings generated profit
100%
Average Return
+165.00%
reiterated a xxx
 rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +165.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CNTX Analyst Recommendation Trends

Rating
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Strong Buy
5
4
5
5
8
Buy
3
3
3
2
3
Hold
0
1
28
33
68
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
8
36
40
79
In the current month, CNTX has received 11 Buy Ratings, 68 Hold Ratings, and 0 Sell Ratings. CNTX average Analyst price target in the past 3 months is 5.43.
Each month's total comprises the sum of three months' worth of ratings.

CNTX Financial Forecast

CNTX Earnings Forecast

Next quarter’s earnings estimate for CNTX is -$0.11 with a range of -$0.14 to -$0.04. The previous quarter’s EPS was -$0.14. CNTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CNTX has Performed in-line its overall industry.
Next quarter’s earnings estimate for CNTX is -$0.11 with a range of -$0.14 to -$0.04. The previous quarter’s EPS was -$0.14. CNTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CNTX has Performed in-line its overall industry.
No data currently available

CNTX Sales Forecast

Next quarter’s sales forecast for CNTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CNTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CNTX has Performed in-line its overall industry.
Next quarter’s sales forecast for CNTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CNTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CNTX has Performed in-line its overall industry.

CNTX Stock Forecast FAQ

What is CNTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Context Therapeutics’s 12-month average price target is 5.43.
    What is CNTX’s upside potential, based on the analysts’ average price target?
    Context Therapeutics has 99.63% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CNTX a Buy, Sell or Hold?
          Context Therapeutics has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Context Therapeutics’s price target?
            The average price target for Context Therapeutics is 5.43. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $7.00 ,the lowest forecast is $3.02. The average price target represents 99.63% Increase from the current price of $2.72.
              What do analysts say about Context Therapeutics?
              Context Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of CNTX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.